Ocular surface inflammatory mediator

"Ocular surface inflammatory mediators" is not a single molecule or receptor but rather refers to a broad group of signaling proteins—including **cytokines** such as interleukin‑1β (IL‑1β), tumor necrosis factor alpha (TNF‑α), interleukin‑6 (IL‑6), interleukin‑8 (IL‑8), interferon gamma (IFN‑γ), and matrix metalloproteinase 9 (**MMP–9**)—that are released by epithelial cells and immune cells on the ocular surface in response to stress or injury. These mediators play central roles in the pathogenesis of **dry eye disease** and other ocular inflammatory disorders by promoting immune cell recruitment, tissue damage, tear film instability, and chronic inflammation[2][3][4][5]. They are not considered therapeutic targets themselves but represent a class of molecules that are targeted collectively by anti-inflammatory therapies. The presence or elevation of certain mediators like MMP–9 serves as a biomarker for clinically significant ocular inflammation[3]. Because this term does not refer to one specific targetable molecule or receptor but rather an entire class/family involved in immune signaling on the ocular surface, it is not suitable as an individual drug target entry. Key points supporting "is_incorrect": *The term describes multiple molecules with overlapping functions rather than one canonical druggable target; thus it cannot be mapped to standard structured information for receptors/enzymes/transporters/etc.[2][3]*

Other names

Inflammatory mediators of the ocular surfacePro-inflammatory cytokines in dry eyeOcular surface cytokines

Inhibition of pro-inflammatory cytokine production[2][3][5] Suppression of T-cell activation and migration[2][5]